| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 46,400 | 47,200 | 17:19 | |
| 46,400 | 47,200 | 17:03 |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 01.10. | Otsuka-Aktie heute stark gefragt: Kurs legt deutlich zu (47,60 €) | Die Aktie von Otsuka zählt am Mittwoch zu den großen Gewinnern an der Börse. Der Titel steigt deutlich. Zu den Performancebesten am Aktienmarkt zählt zur Stunde der Anteilsschein von Otsuka. Im Vergleich... ► Artikel lesen | |
| 22.09. | FDA turns down Lundbeck, Otsuka's Rexulti in PTSD on lack of efficacy data | ||
| 20.09. | H. Lundbeck A/S: Otsuka and Lundbeck receive Complete Response Letter from U.S. FDA for sNDA of REXULTI (brexpiprazole) in combination with sertraline for the treatment of adults with PTSD | Valby, Denmark, 20 September 2025 - H. Lundbeck A/S (Lundbeck) and Otsuka America Pharmaceutical, Inc., (Otsuka) announce that Otsuka has received a Complete Response Letter (CRL) from the U.S. Food... ► Artikel lesen | |
| 19.09. | Esperion Says Its Partner Otsuka Receives Japan Marketing Approval For NEXLETOL To Treat Cholesterol | ||
| 19.09. | Esperion Therapeutics, Inc.: Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL in Japan for the Treatment of Hypercholesterolemia |
